No Data
No Data
Nvidia Is Up 186% From A Year Ago, Yet These 7 Stocks Have More Than Doubled Their Returns Over The AI Chipmaker
NVIDIA has been the standout tech stock of the past year, leading the Nasdaq 100 index in the performance ranking.
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $59
Stifel analyst Dae Gon Ha maintains $Soleno Therapeutics(SLNO.US)$ with a buy rating, and maintains the target price at $59.According to TipRanks data, the analyst has a success rate of 36.2% and a to
Piper Sandler Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $93
Piper Sandler analyst Yasmeen Rahimi maintains $Soleno Therapeutics(SLNO.US)$ with a buy rating, and maintains the target price at $93.According to TipRanks data, the analyst has a success rate of 35.
Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Soleno Therapeutics (SLNO)
Soleno Therapeutics Announces Oral Presentation Featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024
Soleno Therapeutics, Inc. (NASDAQ: SLNO) today announced that data from the randomized withdrawal period of Study C602 of DCCR (diazoxide choline) extended-release tablets in Prader-Willi Syndrome (PWS) will be featured in an oral presentation at the Annual Meeting of the Endocrine Society (ENDO 2024), being held June 1-4, 2024 in Boston, Massachusetts.
Soleno Therapeutics to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,